key: cord-0751167-066rysjh
authors: Liu, T.; Wu, S.; Tao, H.; Zeng, G.; Zhou, F.; Guo, F.; Wang, X.
title: Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan -implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
date: 2020-06-16
journal: nan
DOI: 10.1101/2020.06.13.20130252
sha: 1cd84e95011a88aa226611825245c511b2653223
doc_id: 751167
cord_uid: 066rysjh

Background It is to be determined whether people infected with SARS-CoV-2 will develop long-term immunity against SARS-CoV-2 and retain long-lasting protective antibodies after the infection is resolved. This study was to explore to explore the outcomes of IgG antibodies to SARS-CoV-2 in four groups of individuals in Wuhan, China. Methods We included the following four groups of individuals who received both COVID-19 IgM/IgG tests and RT-PCR tests for SARS-CoV-2 from February 29, 2020 to April 29, 2020: 1470 hospitalized patients with COVID-19 from Leishenshan Hospital, Zhongnan Hospital of Wuhan University, and Wuhan No. 7 Hospital, 3832 healthcare providers without COVID-19 diagnosis, 19555 general workers, and 1616 other patients to be admitted to the hospital (N=26473). COVID-19 patients who received IgM/IgG tests <21 days after symptom onset were excluded. Results IgG prevalence was 89.8% (95% CI 88.2-91.3%) in COVID-19 patients, 4.0% (95% CI 3.4-4.7%) in healthcare providers, 4.6 (95% CI 4.3-4.9 %) in general workers, and 1.0% in other patients (p all <0.001 for comparisons with COVID-19 patients). IgG prevalence increased significantly by age among healthcare workers and general workers. Prevalence of IgM antibodies to SARS-CoV-2 was 31.4% in COVID-19 patients, 1.5% in healthcare providers, 1.3% in general workers, and 0.2% in other patients. Conclusions Very few healthcare providers had IgG antibodies to SARS-CoV-2, though a significant proportion of them had been infected with the virus. After SARS-CoV-2 infection, people are unlikely to produce long-lasting protective antibodies against this virus.

Currently, coronavirus disease in 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1-4 has become a global pandemic. The virus was freely transmitted among residents in the communities [5] [6] [7] [8] in Wuhan, China from late November 2019 till several days after the lockdown of the city on January 23, 2020.

Most of SARS-CoV-2 infections do not require medical attention [9] [10] [11] and only about 5% COVID-19 cases in China need intensive care 12 Among those therapeutic approaches, Remdesivir is most promising so far, although an underpowered trial failed to demonstrate treatment benefits. 15, 16 The presence of SARS-CoV-2 in COVID-19 patients is usually confirmed using realtime reverse-transcriptase polymerase chain reaction (RT-PCR) method. [17] [18] [19] Due to sample collection method, discrepancies in personnel skills training and low virus load in throat swabs after symptom onset 20 , RT-PCR methods have high false-negative test results 19, 21, 22 . Several days after symptom onset when infected patients start to seek medical attention, virus load in clinical specimens of upper respiratory tract will become All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint relatively low 20,23 . It often takes two or three repeatedly collected specimens to get a positive test result in COVID-19 patients. SARS-CoV-2 enters respiratory epithelial cells via interactions with angiotensin converting enzyme 2 (ACE2) 24 Additionally, some patients had recurrent positive RT-PCR tests on nasal or throat swabs after recovered from COVID-19. 28 It still unknown whether COVID-19 patients will develop long-term immunity against SARS-CoV-2 and retain long-lasting protective antibodies after the infection is resolved. Large-scale sero-epidemiological studies are also needed to assess infection attack rates and disease incidence in the population and herd immunity. In this study, we reported the experiences in COVID-19 IgM/IgG testing in Wuhan. We assessed prevalence of IgG antibodies against SARS-CoV-2 in hospitalized patients with COVID-19 from Zhongnan Hospital of Wuhan University and Leishenshan Hospital (set up on an emergency basis to admit COVID-19 patients and managed by Zhongnan Hospital of Wuhan University), and Wuhan No. 7 Hospital, healthcare providers without a confirmed COVID-19 diagnosis working in Zhongnan Hospital of Wuhan University, and people from the general population in Wuhan. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06. 13.20130252 doi: medRxiv preprint Considering that Wuhan was the early epicenter of COVID-19 outbreak, most of these healthcare providers would be inevitably exposed to SARS-CoV-2 during the early days of the outbreak (from late November 2019 to January 20, 2020) when person-to-person transmission was not suspected and little personal protection against this virus was employed among medical personnel, a significant proportion of whom would get infected with the virus.

Mean age was 58.7 years in 1470 COVID-19 patients, 37.1 years in 3832 healthcare providers, 41.6 years in 19555 general workers and 53.3 years in other patients ( Table   1 ). Hospitalized COVID-19 patients were composed of more older people, while healthcare providers and general workers were mostly young adults. Among COVID-19 patients, median time from symptom onset to IgM/IgG test was 41 days (interquartile range 33-50 days). The last RT-PCR tests for SARS-CoV-2 were positive in only eight COVID-19 patients and none of three patients was tested negative for IgG antibodies to SARS-CoV-2.

Prevalence of IgG antibodies to SARS-CoV-2 was 89.8% (95% CI 88.2-91.3%) in All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3) .

Among COVID-19 patients, mean age was similar between those with IgG antibodies to SARS-CoV-2 and those without ( Table 4) . Presence of IgG antibodies to SARS-CoV-2 was not associated with most demographic characteristics, disease severity, presence of comorbidities, treatment received, and clinical characteristics, except for antibiotics treatment, chloroquine/hydroxychloroquine treatment, and needing intubation. IgG prevalence and IgM prevalence among hospitalized patients with COVID-19 by demographic and clinical characteristics are presented in Table 5 . Mortality rate was 1.3% (95% CI 0.7-1.9%) in those with IgG antibodies to SARS-CoV-2 and was 3.3% (95% CI 0.4-6.2%) in those without (Figure 1) . Mortality risk was similar between those with IgG antibodies to SARS-CoV-2 and those without (adjusted hazard ratio 0.45 95% CI 0.16-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint 1.24, P=0.12).

We analyzed prevalence of IgG antibodies to SARS-CoV-2 in hospitalized COVID-19 patients, healthcare providers without a confirmed COVID-19 diagnosis, general workers, and other patients to be admitted to hospital. The most intriguing finding of this study is that only 4% of healthcare providers without confirmed COVID-19 diagnosis had IgG antibodies to SARS-CoV-2 in their blood. Most of the healthcare providers were exposed to SARS-CoV-2 during the first few months of the outbreak when use of personal protection equipment was sparse as person-to-person transmission was not suspected. COVID-19 IgM/IgG tests in the US and around the world as reported in the news constantly showed that the true infection rate would be 10 to 80 times higher than that had been confirmed by RT-PCR tests for SARS-CoV-2. Seroprevalence of antibodies to SARS-CoV-2 in 1021 people before resuming work from April 3 to 15, 2020 in Wuhan was reported to be ~10%, 29 about 20 times higher than the infection attack rate calculated from the confirmed COVID-19 cases. In New York City, a 21.2% positive rate was reported with young and middle-aged people having the highest positive rate. The proportion of people infected with SARS-CoV-2 who have no symptom or only mild symptoms that do not need medical attention or hospitalization may account for the majority of SARS-CoV-2 infections. Currently, no effective therapeutics are available for treating COVID-19 patients. Detecting patients with SARA-CoV-2 infection who are not in urgent need of hospitalization will provide no All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint benefit to these patients, though it may have important public health applications in tracing their close contacts and preventing these people from spreading the infection to others. In Zhongnan Hospital of Wuhan University, 2.88% (118/4099) healthcare workers were diagnosed with COVID-19 before March 16, 2020. With a moderate estimation, the true infection rate would be ten times that had been confirmed, i.e., >25% of those healthcare providers without diagnosed COVID-19 had been infected. However, only 4% of those infected healthcare workers without confirmed COVID-19 still had IgG antibodies to SARS-CoV-2. They just got infected with SARS-CoV-2 and cleared the virus by their own immune systems. No long-lasting protective antibodies against SARS-CoV-2 were produced in these healthcare providers. Our observed high prevalence of IgG antibodies to SARS-CoV-2 in older groups (60-69 years old and ≥ 70 years old) among health care workers and general worker in Wuhan also raised the concern that IgG antibodies to SARS-CoV-2 would be lost some time after the infection was cleared, as young or middle-aged people usually took more social responsibilities and had higher chances to get infected during lockdown of the city. We also found that >10% of confirmed COVID-19 cases had no detectable serum levels of IgG antibodies to SARS-CoV-2 after 21 days post symptom onset. They were unlikely to not produce IgG antibodies to SARS-CoV-2 after being infected with the virus 20,24-26,30 . Long et al reported that after 17-19 days post symptom onset, IgG was positive in all patients with COVID-19. 30 Lack of blood samples >17 days post symptom onset may be responsible for negative IgG tests in some patients reported in previous literatures. 25, 26 Therefore, >10% patients in our study who had no IgG antibodies after 21 days post symptom onset most likely lost those IgG antibodies after the infection was resolved. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. to SARS-CoV-2 and every human being in the world was susceptible to this virus before it first jumped from wild animals to humans. It might be due to the dramatic differences between SARS-CoV-1 and SARS-CoV-2 in the receptor-binding region of Spike protein and the key amino acid residues involved in the interaction with human ACE2. 24

Neutralizing antibodies to SARS-CoV-1 may not produce reliable immunoprotection against SARS-CoV-2. However, why long-lasting protective antibodies are not produced after SARS-CoV-2 infection is still to be studied. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06. 13.20130252 doi: medRxiv preprint Are IgG antibodies to SARS-CoV-2 parts of short-term immunity against this virus? It is reported that after infected with SARS-CoV-2, rhesus macaques produced antibodies that exhibited neutralizing activity against SARS-CoV-2 in vitro, and re-challenge with the same viral dose weeks post initial infection was not successful. 41, 42 This indicates that short-term neutralizing antibodies may be produced in this animal model. However, infected monkeys have a faster viral clearance mechanism than humans and reinfection protection for humans even in a short time period after the initial infection might not necessarily happen. We found mortality risks were similar between hospitalized COVID-19 patients with IgG antibodies to SARS-CoV-2 and those without, which indicates that absence of IgG antibodies may not affect clinical end outcome and IgG antibodies may even not be part of short-term protective immune response against SARS-CoV-2.

Whether therapeutic antibodies targeting the spike protein are effective is also a question. A recent study characterized the viral spike protein receptor-binding domainspecific monoclonal antibodies derived from single B cells of patients with COVID-19. 43 In that study, the three most server cases (one dead) had much higher plasma binding activities to SARS-CoV-2 spike protein, spike protein receptor-binding domain, and nucleocapsid protein than the other five cases with mild symptoms, which casts some doubts on the relationship between antibody response and disease progression and the utilization of neutralizing antibodies as prophylactic and therapeutic SARS-CoV-2 interventions. Antibody-dependent enhancement of viral entry via the binding of those neutralizing antibodies and the spike protein is also a big concern to be closely monitored [44] [45] [46] [47] .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. Third, as serum COVID-19 IgM/IgG level can become undetectable after recovery in patients with SARS-CoV-2 infections, COVID-19 IgM/IgG test will not be a reliable tool for the surveillance of past infections of SARS-CoV-2 in areas where the epidemic is over. Finally, in our study, most of the healthcare providers without a confirmed COVID-19 diagnosis have been exposed to the wild-type SARS-CoV-2 virus in a highly contagious environment. However, none of them developed long-lasting protective antibodies against SARS-CoV-2. These findings raise the concern if the inactivated virus, subunit, and recombinant vaccines currently under development will be able to induce effective immune protections against SARS-CoV-2.

The main strength of this study is that we analyzed data on COVID-19 IgM/IgG tests on a large cohort of individuals from two hospitals in Wuhan, the epicenter of COVID-19 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint outbreak in China. Antibody tests on healthcare providers provided valuable information on outcomes of SARS-CoV-2 infections. Limitations of this study include that we do not have long-term follow-up data on recovered COVID-19 patients. Whether or not those patients will lose COVID-19 IgG antibodies in the next few months is still to be studied.

Additionally, COVID-19 IgM/IgG test does not have perfect sensitivity and specificity for detecting IgG antibodies to SARS-CoV-2 in the serum. Nevertheless, we observed that very few healthcare providers without a confirmed COVID-19 diagnosis had a positive test result. This observed phenomenon strongly suggests that long-term protective antibodies are unlikely produced after SARS-CoV-2 infection.

In conclusion, very few healthcare providers without confirmed COVID-19 diagnosis in Wuhan have IgG antibodies to SARS-CoV-2, though a substantial portion of them had been infected with the virus. More than 10% of COVID-19 patients did not have those antibodies after 21 days post symptom onset. After SARS-CoV-2 infection, people are unlikely to produce long-lasting protective antibodies against this virus. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. IgM/IgG tests and RT-PCR tests for SARS-CoV-2 from February 29 to April 5, 2020 (the last test result was used for analyses). Eighty-four patients were transferred from Zhongnan Hospital of Wuhan University to Leishenshan Hospital and were only counted once each. We excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop. There were 4099 healthcare providers working in Zhongnan All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. 11 There were changes in diagnosis of COVID-19 in China, and the case definition was gradually broadened to allow for detection of milder cases. 49 The confirmed cases were estimated to be 4 times less than that if the later broader case definition had been adopted earlier. Severity of status of patients with COVID-19 at All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint admission was defined as moderate, severe, or critical. Patients with mild diseases were not admitted to the above three hospitals and were generally admitted to Fangcang Hospitals (makeshift hospitals).

Clinical specimens collection and RT-PCR test for SARS-CoV-2 were previously (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. 

Serum samples from these people were collected. Methods for testing serum IgM and IgG antibodies to SARS-CoV-2 were previously described. 50 COVID-19 IgM/IgG test kits contained recombinant SARS-CoV-2 antigens (spike protein and nucleocapsid protein)

labelled with magnetic beads (tested on a fully automated chemiluminescence immunoassay analyzer) or colloidal gold (test card), anti-human IgM monoclonal antibody, and anti-human IgG monoclonal antibody. These test kits were reported to have high sensitivity and specificity 27,50 . According to the manufacturers, the sensitivity and specificity are ~90% and >99% for IgM, and ~98% and ~98% for IgG, respectively. Two physicians extracted the following data using data collection form from electronic medical records: demographic information such as age and sex, RT-PCR test date and results, COVID-19 IgM/IgG test date and results, date of symptom onset for COVID-19 patients, treatments received, and clinical outcomes. Another physician in the research team reviewed the collected data.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Adjusted hazard ratio and 95% CI were calculated by fitting a Cox proportional hazard model, controlling for age, sex, and severity of COVID-19 at admission. Statistical analyses were conducted using SAS software version 9.4 (SAS Institute; Carey, NC). A 2-sided p value of <0.05 was considered statistically significant. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. Negative: patients who did not have IgG antibodies to SARS-CoV-2.

Adjust hazard ratio: adjusted for age, sex, and severity of COVID-19 at admission. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130252 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam

novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China

Clinical Characteristics of Coronavirus Disease 2019 in China

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

First Case of 2019 Novel Coronavirus in the United States

Remdesivir in adults with severe COVID-19: a randomised, double-blind

Clinical features of patients infected with

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

COVID-19: immunopathology and its implications for therapy

The potential danger of suboptimal antibody responses in COVID-19

The convalescent sera option for containing COVID-19

Effect of Changing Case Definitions for COVID-19 on the Epidemic Curve and Transmission Parameters in Mainland China: A Modelling Study. The Lancet Public health

Antibodies in Infants Born to Mothers With

) Cardiovascular disease (any) No 997 90.5 (88.6-92.3) 31.7 (28.8-34.6)